{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:52:18Z","timestamp":1770742338784,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which may generate unusual COVID-19 dynamics and pose unique management challenges. We report the unusual clinical course of COVID-19 in a patient with mantle cell lymphoma (MCL) exposed to nine doses of Rituximab shortly before infection with severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). He had a prolonged asymptomatic phase, with negative molecular and antibody testing for SARS-CoV-2, followed by a rapidly progressive evolution to severe COVID-19. Despite detection of viral RNA overlapped with first symptoms occurrence, anti-SARS-CoV-2 antibodies displayed an asynchronous pattern, with IgG first appearing 2\u00a0days after RNA positivity and IgM never being detected throughout the entire clinical course. While disease-associated immune derangements and\/or previous treatments involving anti-CD20 antibodies might have contributed to COVID-19 dynamics in our patient, data suggests that antibody testings, without concurrent molecular assessment for SARS-CoV-2, may turn inadequate for monitoring of MCL patients, and in general NHL patients heavily exposed to anti-CD20 antibodies, during the current pandemics. We suggest that repeated molecular testing of nasopharyngeal swab should be implemented in these subjects despite a negative serology and absence of symptoms of SARS-CoV-2 infection. For the same reasons, a customized strategy needs to be developed for patients exposed to anti-CD20 antibodies, based on different features and mechanism of action of available SARS-CoV-2 vaccines and novel vaccinomics developments.<\/jats:p>","DOI":"10.1186\/s13027-021-00376-1","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T09:04:59Z","timestamp":1622624699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab"],"prefix":"10.1186","volume":"16","author":[{"given":"Gianpaolo","family":"Marcacci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Volzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Donnarumma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"D\u2019Ovidio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Micallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Portella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarosaria","family":"De Chiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Crisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"3","key":"376_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(20)30096-6.","journal-title":"Lancet Oncol"},{"issue":"10241","key":"376_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","volume":"395","author":"LY Lee","year":"2020","unstructured":"Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(20)31173-9.","journal-title":"Lancet."},{"issue":"8","key":"376_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.annonc.2020.04.006","volume":"31","author":"H Miyashita","year":"2020","unstructured":"Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31(8):1088\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.006.","journal-title":"Ann Oncol"},{"issue":"6","key":"376_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","volume":"34","author":"W He","year":"2020","unstructured":"He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637\u201345. https:\/\/doi.org\/10.1038\/s41375-020-0836-7.","journal-title":"Leukemia."},{"issue":"2","key":"376_CR5","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1111\/bjh.16852","volume":"190","author":"JA Aries","year":"2020","unstructured":"Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol. 2020;190(2):e64\u20137. https:\/\/doi.org\/10.1111\/bjh.16852.","journal-title":"Br J Haematol"},{"issue":"10241","key":"376_CR6","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. COVID-19 and Cancer consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(20)31187-9.","journal-title":"Lancet."},{"issue":"1","key":"376_CR7","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/bjh.16801","volume":"190","author":"F Mart\u00edn-Moro","year":"2020","unstructured":"Mart\u00edn-Moro F, Marquet J, Piris M, Michael BM, S\u00e1ez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190(1):e16\u201320. https:\/\/doi.org\/10.1111\/bjh.16801.","journal-title":"Br J Haematol"},{"issue":"10","key":"376_CR8","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. ITA-HEMA-COV investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737\u201345. https:\/\/doi.org\/10.1016\/S2352-3026(20)30251-9.","journal-title":"Lancet Haematol"},{"issue":"12","key":"376_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3324\/haematol.2016.149252","volume":"101","author":"WB Stevens","year":"2016","unstructured":"Stevens WB, Netea MG, Kater AP, van der Velden WJ. 'Trained immunity': consequences for lymphoid malignancies. Haematologica. 2016;101(12):1460\u20138. https:\/\/doi.org\/10.3324\/haematol.2016.149252.","journal-title":"Haematologica."},{"issue":"10","key":"376_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/cas.13020","volume":"107","author":"XY Zhang","year":"2016","unstructured":"Zhang XY, Xu J, Zhu HY, Wang Y, Wang L, Fan L, et al. Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci. 2016;107(10):1471\u20136. https:\/\/doi.org\/10.1111\/cas.13020.","journal-title":"Cancer Sci"},{"key":"376_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33. https:\/\/doi.org\/10.3389\/fimmu.2019.00033.","journal-title":"Front Immunol"},{"issue":"9","key":"376_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/M20-0504","volume":"172","author":"SA Lauer","year":"2020","unstructured":"Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577\u201382. https:\/\/doi.org\/10.7326\/M20-0504.","journal-title":"Ann Intern Med"},{"issue":"6","key":"376_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845\u20138. https:\/\/doi.org\/10.1038\/s41591-020-0897-1.","journal-title":"Nat Med"},{"issue":"10","key":"376_CR14","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1073\/pnas.1808849116","volume":"116","author":"JG Cullen","year":"2019","unstructured":"Cullen JG, McQuilten HA, Quinn KM, Olshansky M, Russ BE, Morey A, et al. CD4+ T help promotes influenza virus-specific CD8+ T cell memory by limiting metabolic dysfunction. Proc Natl Acad Sci U S A. 2019;116(10):4481\u20138. https:\/\/doi.org\/10.1073\/pnas.1808849116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"376_CR15","doi-asserted-by":"publisher","first-page":"894b","DOI":"10.1182\/blood.V90.2.894b","volume":"90","author":"JL Preud'homme","year":"1997","unstructured":"Preud'homme JL, Gombert J, Brizard A, Lacotte L, Babin P, Flandrin G. Serum Ig Abnormalities in Mantle Cell Lymphoma. Blood. 1997;90:894b\u20135.","journal-title":"Blood"},{"issue":"26","key":"376_CR16","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","volume":"118","author":"OE Yri","year":"2011","unstructured":"Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nord\u00f8y T, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769\u201371. https:\/\/doi.org\/10.1182\/blood-2011-08-372649.","journal-title":"Blood."},{"issue":"11","key":"376_CR17","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","volume":"122","author":"I Nazi","year":"2013","unstructured":"Nazi I, Kelton JG, Larch\u00e9 M, Snider DP, Heddle NM, Crowther MA, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946\u201353. https:\/\/doi.org\/10.1182\/blood-2013-04-494096.","journal-title":"Blood."},{"issue":"10","key":"376_CR18","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","volume":"186","author":"D Bedognetti","year":"2011","unstructured":"Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186(10):6044\u201355. https:\/\/doi.org\/10.4049\/jimmunol.1004095.","journal-title":"J Immunol"},{"issue":"20","key":"376_CR19","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1615.","journal-title":"Cancer Res"},{"issue":"8","key":"376_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.annonc.2020.04.475","volume":"31","author":"ML Solodky","year":"2020","unstructured":"Solodky ML, Galvez C, Russias B, Detourbet P, N'Guyen-Bonin V, Herr AL, et al. Lower detection rates of SARS-COV1 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19. Ann Oncol. 2020;31(8):1087\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.475.","journal-title":"Ann Oncol"},{"issue":"2","key":"376_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","volume":"190","author":"PR Tepasse","year":"2020","unstructured":"Tepasse PR, Hafezi W, Lutz M, K\u00fchn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190(2):185\u20138. https:\/\/doi.org\/10.1111\/bjh.16896.","journal-title":"Br J Haematol"},{"key":"376_CR22","doi-asserted-by":"publisher","unstructured":"Betrains A, Godinas L, Woei-A-Jin FJSH, Rosseels W, Van Herck Y, Lorent N, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.17266 Epub ahead of print. PMID: 33314018.","DOI":"10.1111\/bjh.17266"},{"issue":"11","key":"376_CR23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.clml.2020.08.017","volume":"20","author":"H Yasuda","year":"2020","unstructured":"Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774\u20136. https:\/\/doi.org\/10.1016\/j.clml.2020.08.017.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"376_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3389\/fonc.2020.01578","volume":"10","author":"I Kos","year":"2020","unstructured":"Kos I, Balensiefer B, Roth S, Ahlgrimm M, Sester M, Schmidt T, et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol. 2020;10:1578. https:\/\/doi.org\/10.3389\/fonc.2020.01578.","journal-title":"Front Oncol"},{"key":"376_CR25","doi-asserted-by":"publisher","unstructured":"Gerber V, Velay A, Boehn L, Solis M, Kaeuffer C, Rougier E, et al. Protracted SARS-CoV-2 pneumonia with rituximab treatment: about two cases. J Med Virol. 2021. https:\/\/doi.org\/10.1002\/jmv.26921 Epub ahead of print. PMID: 33666242.","DOI":"10.1002\/jmv.26921"},{"issue":"1","key":"376_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garc\u00eda-Su\u00e1rez","year":"2020","unstructured":"Garc\u00eda-Su\u00e1rez J, de la Cruz J, Cedillo \u00c1, Llamas P, Duarte R, Jim\u00e9nez-Yuste V, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133. https:\/\/doi.org\/10.1186\/s13045-020-00970-7.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"376_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/bjh.15722","volume":"184","author":"N Mart\u00ednez-Calle","year":"2019","unstructured":"Mart\u00ednez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, et al. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Br J Haematol. 2019;184(6):957\u201368. https:\/\/doi.org\/10.1111\/bjh.15722.","journal-title":"Br J Haematol"},{"key":"376_CR28","doi-asserted-by":"publisher","unstructured":"Favalli EG, Maioli G, Biggioggero M, Caporali R. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev Clin Immunol. 2021:1\u201311. https:\/\/doi.org\/10.1080\/1744666X.2021.1908887 Epub ahead of print. PMID: 33787418.","DOI":"10.1080\/1744666X.2021.1908887"},{"key":"376_CR29","doi-asserted-by":"publisher","first-page":"102306","DOI":"10.1016\/j.msard.2020.102306","volume":"44","author":"V Meca-Lallana","year":"2020","unstructured":"Meca-Lallana V, Aguirre C, R\u00edo B, Carde\u00f1oso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with anti-CD20 therapies. Mult Scler Relat Disord. 2020;44:102306. https:\/\/doi.org\/10.1016\/j.msard.2020.102306.","journal-title":"Mult Scler Relat Disord"},{"key":"376_CR30","doi-asserted-by":"publisher","unstructured":"Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study [published online ahead of print, 2021 Mar 25]. Lancet Rheumatol. 2021. https:\/\/doi.org\/10.1016\/S2665-9913(21)00059-X.","DOI":"10.1016\/S2665-9913(21)00059-X"},{"key":"376_CR31","doi-asserted-by":"crossref","unstructured":"Lamure S, Dulery R, Delord M, et al. High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy. AACR Virtual Meeting: COVID-19 and Cancer. Abstract S09\u201302.","DOI":"10.1158\/1557-3265.COVID-19-21-S09-02"},{"issue":"8","key":"376_CR32","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","volume":"2","author":"L Garcia-Montoya","year":"2020","unstructured":"Garcia-Montoya L, Villota-Eraso C, Md Yusof MY, Vital EM, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. Lancet Rheumatol. 2020;2(8):e497\u2013509. https:\/\/doi.org\/10.1016\/S2665-9913(20)30033-3.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"376_CR33","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Fo\u00e0 R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5(6):826\u201337. https:\/\/doi.org\/10.4161\/mabs.26008.","journal-title":"MAbs."},{"issue":"1","key":"376_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28. https:\/\/doi.org\/10.1038\/s41541-021-00292-w.","journal-title":"NPJ Vaccines"},{"key":"376_CR35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3389\/fonc.2020.01267","volume":"10","author":"T Assi","year":"2020","unstructured":"Assi T, Samra B, Dercle L, Rassy E, Kattan J, Ghosn M, et al. Screening strategies for COVID-19 in patients with hematologic malignancies. Front Oncol. 2020;10:1267. https:\/\/doi.org\/10.3389\/fonc.2020.01267.","journal-title":"Front Oncol"},{"issue":"4","key":"376_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195\u20137. https:\/\/doi.org\/10.1038\/s41577-021-00526-x.","journal-title":"Nat Rev Immunol"},{"key":"376_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13582","volume":"204","author":"SC Jordan","year":"2021","unstructured":"Jordan SC. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol. 2021;204:310\u201320. https:\/\/doi.org\/10.1111\/cei.13582. Epub ahead of print. PMID: 33534923.","journal-title":"Clin Exp Immunol"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-021-00376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-021-00376-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-021-00376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T11:54:44Z","timestamp":1672314884000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-021-00376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["376"],"URL":"https:\/\/doi.org\/10.1186\/s13027-021-00376-1","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a non-interventional study on archived tissue samples and all clinical procedures were performed within standard clinical guidelines of all involved Institutions. All patients accessing the Istituto Nazionale Tumori of Naples, consent to use of clinical samples for academic research and all performed procedures were in accordance with the ethical standards of the institutional research committees of participating institutions, with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}